The inhibition of TIM-3/gal-9 binding in “vitro” reduced the proliferation capacity of AML cells [154], and, in murine models, an anti-human TIM-3 MoAb eliminated LSCs without affecting normal hematopoiesis [145]. The gene discussed is HAVCR2; the disease is acute myeloid leukemia.